Dr. John Wroblewski Joins Ohr Pharmacuetical’s Ophthalmic Advisory Board

New York-based Ohr Pharmaceutical named John Wroblewski, MD, to its ophthalmic scientific advisory board.

Advertisement

Dr. Wroblewski is a board-certified ophthalmologist with an expertise in diseases of the retina, macula and vitreous. He’s a senior partner at Cumberland Valley Retina Consultants in Chambersburg, Pa.

The advisory board’s retinal ophthalmology experts give guidance on clinical programs, regulatory issues and more. Ohr’s leading drug candidate is Squalamine for neovascular ophthalmic clinical indications.

More Articles on Ophthalmology:
New Eyes in Las Vegas Hires Cornea Specialist Dr. Ksenia Stafeeva
Clearside Biomedical Appoints Dr. Glenn Noronha as Executive Vice President
Dr. John Ervin Elected President of Georgia Society of Ophthalmology

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.